Completed PHASE2 INTERVENTIONAL NCT00530660

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

An Open-label Phase II Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Heterologous Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Young Adult Population (Follow Up to Study 810501)

Sponsor: Alachua Government Services, Inc.

Conditions Influenza

Interventions H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted

Updated 6 times since 2017 Last updated: Oct 7, 2015 Started: Sep 30, 2007 Primary completion: May 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00530660, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by Alachua Government Services, Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Oct 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alachua Government Services, Inc.

Data source: Alachua Government Services, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria